Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has issued a second complete response letter (CRL) for deramiocel, Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy (DMD), again citing insufficient evidence of effectiveness. Despite the phase 3 HOPE-3 trial meeting its primary endpoint — showing a 54% slowing of upper limb decline — regulators raised concerns about data robustness and analysis plan changes. Capricor is now exploring regulatory pathways in Europe and Japan.
The FDA has dealt Capricor Therapeutics a second blow, issuing another complete response letter (CRL) for deramiocel — an allogeneic cardiosphere-derived cell therapy — in Duchenne muscular dystrophy (DMD). The rejection came just two days before the November 22 action date, following a review that was extended after an FDA advisory panel voted 9–3 that the data did not support the therapy's effectiveness for DMD cardiomyopathy.
Capricor's resubmission leaned heavily on the phase 3 HOPE-3 trial, which enrolled 106 advanced DMD patients and met its primary endpoint, showing a 54% slowing of upper limb muscle decline versus placebo. Cardiac MRI data also suggested a 91% slowing in left ventricular ejection fraction decline. However, the FDA flagged concerns over missing-data handling, post-randomization changes to the statistical analysis plan, and a hypersensitivity imbalance between treatment and placebo groups. Capricor had also filed a major amendment with 24-month open-label extension data and proposed a refined indication for patients older than 9 years — but it wasn't enough.
By the Numbers:
Why it matters: DMD is a devastating, progressive disease with limited treatment options, particularly for older and more severely affected patients. A second FDA rejection is a significant setback for a community with urgent unmet need, and it raises broader questions about the evidentiary standards for cell therapies in rare neuromuscular diseases.